We Did The Math TMSL Can Go To $38
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 10 2025
0mins
Source: NASDAQ.COM
ETF Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $37.77 per unit, indicating a potential upside of 17.08% from its current trading price of $32.27.
Stock Performance Insights: Notable underlying holdings such as Centessa Pharmaceuticals, Kymera Therapeutics, and Primoris Services show significant upside potential based on analyst target prices, raising questions about the validity and optimism of these targets in light of recent market developments.
Analyst Views on CNTA
Wall Street analysts forecast CNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTA is 38.75 USD with a low forecast of 27.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.650
Low
27.00
Averages
38.75
High
62.00
Current: 24.650
Low
27.00
Averages
38.75
High
62.00
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








